This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By prioritizing staff education, starting small with practical applications, and establishing clear guidelines, local health departments can lay the foundation for sustainable AI adoption. This approach ultimately enhances efficiency, improves health outcomes, and ensures cost-effective care for the communities they serve. The post Bridging the AI Gap in Local Health: Practical Steps for Adoption appeared first on MedCity News.
Want to thrive in medical sales? In this episode, TJ, a regional business director specializing in cardiology, shares insider strategies for successfrom fostering a growth mindset to mastering self-leadership. Learn how top performers refine their processes, understand their motivations, and leverage innovation to drive sales in coronary artery disease and structural heart technologies.
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
Forward by Stewart Gandolf, Chief Executive Officer At Healthcare Success, we understand that a patients journey often beings with a search query. In this blog, our Technical Program Manager, Victoria Shepherd, explores the critical role of symptom search optimization. She shares how organizations can leverage this healthcare marketing trend to engage potential patients early and offers key strategies for optimizing symptom-based searches to drive patient conversions.
The US Food and Drug Administration (FDA) has approved Blujepa ( gepotidacin ) antibiotic for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients aged 12 years old and over. The first-in-class bactericidal drug is indicated for such infections caused by E scherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.
The US Food and Drug Administration (FDA) has approved Blujepa ( gepotidacin ) antibiotic for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients aged 12 years old and over. The first-in-class bactericidal drug is indicated for such infections caused by E scherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.
Soleno Therapeutics Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity. The post Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug appeared first on MedCity News.
Automation, AI, budget cuts, and evolving digital strategies have prompted a growing question among pharmaceutical marketing teams: Is my pharma marketing job at risk? As companies adapt to more agile workflows and redefine what modern commercialization looks like, the roles of marketing professionals are being evaluated more critically than ever before.
A well-structured sales compensation plan drives performance, supports business growth, and engages top talent. The right mix of base salary, commission, and bonuses depends on your industry, sales cycle, and hiring strategy. Some businesses emphasize stability with a higher base salary, while others push for aggressive revenue growth with commission-driven models.
As leaders, we often talk about our teams in terms of productivity, performance, and results. But lets take a step back: how often do we define our employees as people first? In a world that emphasizes output, its easy to forget that behind every task and every deadline is a human being with unique skills, dreams, and challenges. When we recognize this, the workplace dynamic transformsimproving not only the atmosphere but also overall performance.
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertexs entry into type 1 diabetes. The post Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal appeared first on MedCity News.
Introduction Weekends may be synonymous with relaxation, but for pharma marketing professionals, they offer an unmatched window to recalibrate. When deadlines arent looming and inboxes arent overflowing, theres finally time to revisit trends, read strategy insights, and uncover tools to elevate your marketing game. The Pharma Marketing Network serves as an ideal destination for this kind of weekend deep-dive.
The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.
MSD (Merck) has gained global rights to develop, manufacture and commercialise an oral small molecule Lipoprotein(a) inhibitor, currently being investigated in a Phase II clinical trial for atherosclerosis.Jiangsu Hengrui Pharmaceuticals Co., Ltd (Hengrui Pharma) has agreed to license its drug candidate HRS-5346 worldwide, excluding the Greater China region.As part of the agreement, MSD will give Hengrui Pharma an initial sum of $200 million in exchange for rights to its Lp(a) inhibitor.
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
CRMs are meant to help companies make better decisions. That said, too many of us end up drowning in dashboards that provide little value (if theyre looked at all). Reports pile up over time, often built in response to ad-hoc requests or leadership demands for more visibility. The result is what we call dashboard explosion, or in other words, a mess of half-built, rarely used, and redundant reports.
Enhancing the accessibility of trustworthy medicines information and the availability of SRDs while also improving search technologies will ensure HCPs can quickly obtain accurate answers to their specific questions. The post The Challenges Of HCPs Accessing Reliable Online Medicines Informationand What Pharma Companies Can Do To Improve Information Sharing appeared first on MedCity News.
Introduction Social media advertising has undergone a major transformation in the pharmaceutical industry over the past decade. What once was a cautious, slow-moving experiment has now become a vital component of modern pharma marketing strategies. The increasing integration of platforms like LinkedIn, X (formerly Twitter), YouTube, and even TikTok has dramatically shifted how pharma brands engage with healthcare professionals (HCPs), patients, and caregivers.
The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A new industry survey from the Biotechnology Innovation Organization (BIO) highlights the vulnerability of supply that proposed tariffs would put on medicines, and its impact on patient access. According to the findings, nearly 90 percent of US biotechs rely on imported components for at least half of their products approved by the US Food and Drug Administration.
LONDON, 25 March 2025 – The Creative Floor Healthcare Awards have awarded this years Talent & Diversity to four charities – Key4Life, The Ideas Foundation, School of Communication of Arts and Brixton Finishing School. The awards continue to be the only health and wellness award show in the world to donate a percentage of profits towards a Talent & Diversity Fund, that helps people from under-represented communities into health and wellness communication agencies.
The FDA approved GSK antibiotic Blujepa as a treatment for uncomplicated urinary tract infections. The drugs novel mechanism of action addresses a broader range of pathogens and could offer a way to lower the potential for drug resistance. The post FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection appeared first on MedCity News.
Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. From generative AI tools that draft emails to predictive algorithms that segment target audiences, the speed and scale of innovation are staggering. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?
The global pharmaceutical & biotechnology environmental monitoring market is expected to expand with a CAGR of 6.2 percent between 2025 and 2031, according a report by Lucintel. Several factors are fuelling this growth, including greater adoption of advanced innovations such as cloud technology, which are driving efficiencies and accuracy, the research highlighted.
By focusing on prevention, collaboration, and data-driven innovation, community health programs are ensuring resources are used more effectively and patient care is proactive rather than reactive. The post How Community Health Programs are Reducing 911 Calls and Helping Patients Before Emergencies appeared first on MedCity News.
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
Introduction Pharmaceutical marketing is entering a new era in 2025, driven by rapid advancements in technology, evolving patient expectations, and tighter compliance demands. As industry leaders adapt to digital-first communication and omnichannel engagement, the need for smart, scalable, and strategic marketing tactics is more urgent than ever. Whether you’re launching a new branded drug or optimizing an established portfolio, staying ahead of the curve in pharmaceutical marketing has be
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
Artificial intelligence (AI) and Big Data are set to remain the most disruptive powers in the healthcare sector for the next two years, with Pharma executives prioritizing these innovations for the near future, according to GlobalData. 1 This report delves into some of the major obstacles and the potential for AI in the pharmaceutical industry. Register now to access exclusive content and insight from: Dr Vladimir Makarov, Programme Manager, The Pistoia Alliance Remco Jan Geukes Foppen, Vincenzo
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
196 
Let's personalize your content